Search results for "PPAR"

showing 10 items of 1686 documents

Comparative cytoprotective effects of carbocysteine and fluticasone propionate in cigarette smoke extract-stimulated bronchial epithelial cells

2013

Cigarette smoke extracts (CSE) induce oxidative stress, an important feature in chronic obstructive pulmonary disease (COPD), and oxidative stress contributes to the poor clinical efficacy of corticosteroids in COPD patients. Carbocysteine, an antioxidant and mucolytic agent, is effec- tive in reducing the severity and the rate of exacerbations in COPD patients. The effects of carbocysteine on CSE-induced oxidative stress in bronchial epithelial cells as well as the comparison of these antioxidant effects of carbocysteine with those of fluticasone propionate are unknown. The present study was aimed to assess the effects of carbocysteine (10−4 M) in cell survival and intracellular reactive o…

medicine.medical_specialtyNecrosisCell SurvivalNF-E2-Related Factor 2Histone Deacetylase 2ApoptosisSettore MED/10 - Malattie Dell'Apparato Respiratoriomedicine.disease_causeBiochemistryFluticasone propionateAntioxidantsCell Linechemistry.chemical_compoundNecrosisInternal medicineparasitic diseasesTobaccomedicineHumansFluticasonechemistry.chemical_classificationReactive oxygen speciesOriginal PaperPlant ExtractsCarbocysteineCarbocysteineEpithelial CellsCell BiologyGlutathioneCigarette smoke . Airway epithelial cells . Reactive oxygen speciesGlutathioneAndrostadienesOxidative StressEndocrinologychemistryApoptosisFluticasonemedicine.symptomReactive Oxygen SpeciesOxidative stressHeme Oxygenase-1medicine.drug
researchProduct

Management of obstructive sleep apnea in Europe.

2011

Objectives: In Europe, the services provided for the investigation and management of obstructive sleep apnoea (OSA) varies from country to country. The aim of this questionnaire-based study was to investigate the current status of diagnostic pathways and therapeutic approaches applied in the treatment of OSA in Europe, qualification requirements of physicians involved in diagnosis and treatment of OSA, and reimbursement of these services. Methods: Two questionnaires were sent to 39 physicians in 22 countries in Europe. In order to standardize the responses, the questionnaire was accompanied by an example. Results: Sleep centers from 21 countries (38 physicians) participated. A broad consist…

medicine.medical_specialtyNeurologyCertificationInternationalityReferralmedicine.medical_treatmentPolysomnographyPolysomnographySettore MED/10 - Malattie Dell'Apparato RespiratorioSurveys and QuestionnairesPositive airway pressuremedicineHumansContinuous positive airway pressureIntensive care medicineReimbursementSleep Apnea ObstructivePublic health services sleep apnea sleep disordered breathing OSA management OSA therapy OSA reibursement OSA treatmentmedicine.diagnostic_testContinuous Positive Airway Pressurebusiness.industrySleep apneaProfessional PracticeMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREGeneral Medicinemedicine.diseaserespiratory tract diseasesObstructive sleep apneaEuropeHealth Care SurveysPublic health servicesSleep apnea Sleep disordered breathing OSA management OSA therapyOSA reimbursement OSA treatmentMedicineHuman medicinebusinessSleep medicine
researchProduct

PPARγ as an indicator of vascular function in an experimental model of metabolic syndrome in rabbits

2021

Abstract Background and aims Underlying mechanisms associated with vascular dysfunction in metabolic syndrome (MetS) remain unclear and can even vary from one vascular bed to another. Methods In this study, MetS was induced by a high-fat, high-sucrose diet, and after 28 weeks, aorta and renal arteries were removed and used for isometric recording of tension in organ baths, protein expression by Western blot, and histological analysis to assess the presence of atherosclerosis. Results MetS induced a mild hypertension, pre-diabetes, central obesity and dyslipidaemia. Our results indicated that MetS did not change the contractile response in either the aorta or renal artery. Conversely, vasodi…

medicine.medical_specialtyNitric Oxide Synthase Type IIIVasodilationmedicine.disease_causeEnosmedicine.arteryInternal medicineAnimalsMedicineRenal arteryProtein kinase BSistema cardiovascularMetabolic SyndromeAortaDiabetisbiologybusiness.industryModels Theoreticalmedicine.diseasebiology.organism_classificationPPAR gammaVasodilationEndocrinologyEndothelium VascularRabbitsSodium nitroprussideMetabolic syndromeCardiology and Cardiovascular MedicinebusinessProto-Oncogene Proteins c-aktOxidative stressmedicine.drugAtherosclerosis
researchProduct

Sleep apnea and its role in transportation safety

2017

Obstructive sleep apnea (OSA) is a main cause of excessive daytime sleepiness and increases the risk for driving accidents, which can be normalized by treatment with continuous positive airway pressure ventilation. Since it is estimated that OSA is not diagnosed in about 80% of cases, recognition of patients at risk for driving accidents is a problem from both medical and societal points of view. Strategies to screen and identify subjects at high risk for driving accidents are under study in order to improve safety on the road, especially for commercial drivers, who show a high prevalence of OSA.

medicine.medical_specialtyObstructive Sleep Apneamedicine.medical_treatmentTransportation safetyExcessive daytime sleepinessReviewSettore MED/10 - Malattie Dell'Apparato RespiratorioGeneral Biochemistry Genetics and Molecular Biologylaw.invention03 medical and health sciences0302 clinical medicinelawCPAPAnesthesiologyDriving accidentmedicineContinuous positive airway pressureGeneral Pharmacology Toxicology and PharmaceuticsOpen peer reviewGeneral Immunology and Microbiologydriving accidentsSleep apneaArticlesGeneral MedicineSleep disordersmedicine.diseaserespiratory tract diseasesObstructive sleep apnea030228 respiratory systemEmergency medicineVentilation (architecture)medicine.symptom030217 neurology & neurosurgery
researchProduct

Cardiovascular risk and events in polycystic ovary syndrome

2009

Young women with polycystic ovary syndrome (PCOS) present a high risk for cardiovascular disease because of the presence of abdominal obesity, insulin resistance and androgen excess. In addition, they present with endothelial dysfunction and early signs of atherosclerosis (increased carotid intima-media thickness and increased coronary calcium). However, the evidence of increased cardiovascular events during the postmenopausal age is relatively small, although some recent studies have indicated a slight increase in the severity of cardiovascular disease in women who had PCOS during their fertile age. The discrepancy between cardiovascular risk in young age and postmenopausal cardiovascular …

medicine.medical_specialtyPCOS Cardiovascular risk myocardial infarction stroke atherosclerosisSettore MED/09 - Medicina InternaDiseaseAndrogen ExcessSeverity of Illness IndexSettore MED/13 - EndocrinologiaInsulin resistanceRisk FactorsInternal medicinePrevalencemedicineHumansEndothelial dysfunctionAbdominal obesityEvidence-Based Medicinebusiness.industryHyperandrogenismObstetrics and GynecologyGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareSettore MED/40 - Ginecologia E OstetriciaPolycystic ovaryPostmenopauseEndocrinologyPremenopauseCardiovascular DiseasesFemalemedicine.symptombusinessDyslipidemiaPolycystic Ovary SyndromeClimacteric
researchProduct

Not all women diagnosed with PCOS share the same cardiovascular risk profiles

2009

Although definitive and confirmatory data are lacking, women with polycystic ovary syndrome (PCOS) are considered to be at increased risk for cardiovascular and metabolic disease. In recent years, the diagnosis of PCOS has broadened considerably to result in several phenotypes. Here we review the evidence for cardiovascular and metabolic risks in PCOS in the classic disorder and the various phenotypes. We conclude that not all women with PCOS should be considered as being similar in terms of cardiovascular risk profiles.

medicine.medical_specialtyPCOS cardiovascular risk hyperandrogenism insulin resistance metabolic syndrome lipid profileendocrine system diseasesRisk profileSettore MED/13 - EndocrinologiaMetabolic DiseasesRisk FactorsInternal medicinemedicineHumansCystMetabolic diseaseVascular diseasebusiness.industrynutritional and metabolic diseasesObstetrics and Gynecologymedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareSettore MED/40 - Ginecologia E OstetriciaPolycystic ovaryObesityfemale genital diseases and pregnancy complicationsPhenotypeEndocrinologyIncreased riskReproductive MedicineCardiovascular DiseasesMetabolomeFemaleMetabolic syndromeHyperandrogenismbusinessPolycystic Ovary SyndromeFertility and Sterility
researchProduct

Jugular pacing lead extraction with laser sheath: a case report.

2010

Over the past 20 years, the number of patients with pacemakers (PM) or implantable cardioverter defibrillators has risen markedly; consequently, an increasing number of lead-removal procedures have become necessary. A 64-year-old woman presenting with an infected device pocket and positive bacterial cultures ( Staphylococcus aureus ) was admitted to our department for lead removal; in 1991, she underwent VVI PM implantation for atrioventricular II degree Mobitz 1 block, and a unipolar lead was introduced via the left jugular vein. The procedure was performed in our Electrophysiology Lab with a cardiac surgeon on standby, using an excimer laser system emitting the energy at the tip of a flex…

medicine.medical_specialtyPacemaker ArtificialProsthesis-Related Infectionslaw.inventionlawPhysiology (medical)Jugular veinlead extracion laser sheatMedicineHumansLead (electronics)Device RemovalEndocarditisbusiness.industryLasersCardiac Pacing ArtificialMiddle AgedStaphylococcal InfectionsLaserSettore MED/11 - Malattie Dell'Apparato CardiovascolareSurgeryCardiothoracic surgeryFluoroscopyFemaleJugular VeinsCardiology and Cardiovascular MedicinebusinessLead extractionEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
researchProduct

Adherence issues related to sublingual immunotherapy as perceived by allergists.

2010

Silvia Scurati1, Franco Frati1, Gianni Passalacqua2, Paola Puccinelli1, Cecile Hilaire1, Cristoforo Incorvaia3, Italian Study Group on SLIT Compliance 1Scientific and Medical Department, Stallergenes, Milan, Italy; 2Allergy and Respiratory Diseases, Department of Internal Medicine, Genoa; 3Allergy/Pulmonary Rehabilitation, ICP Hospital, Milan, ItalyObjectives: Sublingual immunotherapy (SLIT) is a viable alternative to subcutaneous immunotherapy to treat allergic rhinitis and asthma, and is widely used in clinical practice in many European countries. The clinical efficacy of SLIT has been established in a number of clinical trials and meta-analyses. However, because SLIT is self-administered…

medicine.medical_specialtyPathologygenetic structuresefficacyAlternative medicineMedicine (miscellaneous)Adherence Cost Efficacy Side effects Sublingual immunotherapySettore MED/10 - Malattie Dell'Apparato Respiratoriosublingual immunotherapyALLERGENcostmedicineSubcutaneous immunotherapySublingual immunotherapyadherenceClinical efficacyIntensive care medicinePharmacology Toxicology and Pharmaceutics (miscellaneous)sublingual immunoterapyOriginal ResearchAsthmaAEROALLERGENSadherence; sublingual immunotherapy; efficacy; cost; side effectsbusiness.industryHealth Policymedicine.diseaseSliteye diseasesClinical trialside effectsPatient Preference and Adherenceadherence; sublingual immunoterapy; efficacy; cost; side effects.immunotherapysense organsAllergistsADHERENCE TO TREATMENTbusinessSocial Sciences (miscellaneous)
researchProduct

Patient perspectives in the management of asthma: improving patient outcomes through critical selection of treatment options

2010

Asthma is a chronic inflammatory disorder of the airways that requires long-term treatment, the goal of which is to control clinical symptoms for extended periods with the least possible amount of drugs. International guidelines recommend the addition of an inhaled long-acting beta2-agonist (LABA) to a low- to medium-dose inhaled corticosteroid (ICS) when low doses of ICS fail to control asthma symptoms. The fixed combined administration of ICS/LABA improves patient compliance, reducing the risk of therapy discontinuation. The relative deposition pattern of the inhaled drug to the target site is the result of a complex interaction between the device used, the aerosol formulation and the pat…

medicine.medical_specialtyPathologymedicine.drug_classMedicine (miscellaneous)ReviewSettore MED/10 - Malattie Dell'Apparato Respiratoriocompliancedevice treatment inhalers complianceMedicineinhalersIntensive care medicinePharmacology Toxicology and Pharmaceutics (miscellaneous)Asthmatherapybusiness.industryHealth PolicyTreatment optionsAsthma symptomsasthmamedicine.diseaseChronic inflammatory disorderDiscontinuationCorticosteroidBronchoconstrictionFormoterolmedicine.symptombusinessSocial Sciences (miscellaneous)medicine.drugPatient Preference and Adherence
researchProduct

Utility of Intravascular Ultrasound in Percutaneous Revascularization of Chronic Total Occlusions

2016

Intravascular ultrasound has been used for >20 years to guide percutaneous coronary intervention in different subsets of coronary lesions. During the last decade, the interest in percutaneous coronary intervention for chronic total occlusion (CTO) has increased dramatically, leading to high success rates. Failure of guidewire crossing is the most common reason for failed CTO attempts. Certain angiographic features, such as blunt proximal CTO cap, tortuosity, heavy calcification, and lack of visibility of path in the distal vessel, increase procedural difficulty. A better understanding of the behavior of the guidewire within the CTO segment may represent a key issue to achieve successful …

medicine.medical_specialtyPercutaneousmedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentPercutaneous coronary intervention030204 cardiovascular system & hematologyRevascularizationTotal occlusionSettore MED/11 - Malattie Dell'Apparato Cardiovascolare03 medical and health sciences0302 clinical medicineBluntInternal medicineCTO = chronic total occlusion DES = drug-eluting stents IVUS = intravascular ultrasound MACE = major adverse cardiac event(s) PCI = percutaneous coronary interventionIntravascular ultrasoundConventional PCImedicineCardiology030212 general & internal medicineRadiologyCardiology and Cardiovascular MedicinebusinessMace
researchProduct